Evaluating Eli Lilly (LLY): Is the Pharma Giant’s Recent Growth Reflected in Its Current Valuation?

Eli Lilly (LLY) stock has continued its gradual ascent this month, building on a year marked by steady performance. Investors ...

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...
Fintel on MSN

Cantor Fitzgerald Maintains Eli Lilly and (LLY) Overweight Recommendation

Fintel reports that on October 31, 2025, Cantor Fitzgerald maintained coverage of Eli Lilly and (NYSE:LLY) with a Overweight ...
TipRanks on MSN

Eli Lilly (LLY) Says Weight-Loss Pill a Candidate for Fast-Track Approval

U.S. pharmaceutical company Eli Lilly (LLY) says that the weight-loss pill it is developing should be a candidate for ...

Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more ...

Earnings live: Amazon stock soars, Apple pares gains with earnings from AI players to come

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Busy earnings week recap: 'It's all looking pretty positive'

BD8 Capital Partners CEO and CIO, Barbara Doran, joins Market Domination host Josh Lipton to discuss the biggest earnings results that were posted this week, artificial intelligence (AI) demand, and ...